Sitafloxacin

ApprovedSmall molecule

Daiichi Sankyo

Sitafloxacin is one of 135 small molecule programs targeting Abscess. It is currently in Approved.

Indications

Total Trials

Active Trials

134

Competitors

Pipeline

Status by Indication[3][1]

Indication

AbscessActive, not recruiting

PyelonephritisActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

TuberculosisActive, not recruiting

Urinary Tract InfectionActive, not recruiting

AbscessPhase 2

Active, not recruiting

PyelonephritisPhase 2

Active, not recruiting

Chronic Obstructive Pulmonary DiseaseApproved

Active, not recruiting

TuberculosisPhase 3

Active, not recruiting

Urinary Tract InfectionPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

557 competitors in Chronic Obstructive Pulmonary Disease

#DrugCompanyPhaseTrials

Sitafloxacin

Daiichi Sankyo

Approved

1 2

Formoterol Fumarate

AstraZeneca

Preclinical

11 3

Atrovent

Boehringer Ingelheim

Preclinical

5 4

Calciferol

Alnylam Pharmaceuticals

Preclinical

—5

Proventil

Mylan Pharmaceuticals Inc

Preclinical

3 6

Coumadin

AAbbott

Preclinical

1 7

Zoloft

VViatris Specialty LLC

Preclinical

1 8

Narcan

SScienture

Preclinical

1 9

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

—10

Versed

CConrado Roberto Hoffmann Filho

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 3Recruiting

Trial

NCT06905522

Q3 2030

Phase 3Not yet recruiting

Elderly

NCT07076225

Clinical

Trials by Indication[1]

Pyelonephritis1 trial

Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli

Unknown status·MMahidol University·Phase 2·NCT02537847·96 enrolled

Abscess1 trial

Clinical Study on the Early Bactericidal Activity of Sitafloxacin Against Mycobacterium Abscessus Disease

Enrolling by invitation·—·Phase 2·NCT06809413·12 enrolled

Urinary Tract Infection1 trial

Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients

Unknown status·KKhon Kaen University·Phase 2/3·NCT02729116·30 enrolled

Tuberculosis1 trial

Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment

Not yet recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 3·NCT05454345·620 enrolled

Chronic Obstructive Pulmonary Disease1 trial

A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 4·NCT05400369·140 enrolled

2 more indications

Elderly1 trial

Ultra-Short Regimen for Elderly DS-TB

Not yet recruiting·SShenzhen Third People's Hospital·Phase 3·NCT07076225·300 enrolled

Trial1 trial

A PAN-USR TB Multi-Center Trial

Recruiting·SShenzhen Third People's Hospital·Phase 3·NCT06905522·610 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Sitafloxacin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sitafloxacin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sitafloxacin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Daiichi Sankyo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Daiichi Sankyo

Sitafloxacin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Q3 2030

Trials by Indication[1]

Pyelonephritis1 trial

Abscess1 trial

Urinary Tract Infection1 trial

Tuberculosis1 trial

Chronic Obstructive Pulmonary Disease1 trial

Elderly1 trial

Trial1 trial

References

Drug Info

Quick Facts

Related News